The efficacy and safety of combined cancer vaccine and ipilimumab were evaluated in one of the biggest phase III trials for CTLA-4 checkpoint blockade, which enrolled patients who had previously been treated for malignant melanoma. Here, CTLA4 is linked to melanoma.